TY - JOUR T1 - High proportion of post-acute sequelae of SARS-CoV-2 infection in individuals 1-6 months after illness and association with disease severity in an outpatient telemedicine population JF - medRxiv DO - 10.1101/2021.04.24.21256054 SP - 2021.04.24.21256054 AU - James B. O’Keefe AU - H. Caroline Minton AU - Colin Johnson AU - Miranda A. Moore AU - Ghazala A. D. O’Keefe AU - Karima Benameur AU - Jason Higdon AU - Jessica K. Fairley Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/04/27/2021.04.24.21256054.abstract N2 - Background Individuals with coronavirus disease 2019 (COVID-19) may have persistent symptoms following their acute illness. The prevalence and predictors of these symptoms, termed post-acute sequelae of SARS-CoV-2 (PASC), are not fully described.Methods Participants discharged from an outpatient telemedicine program for COVID-19 were emailed a survey (1-6 months after discharge) about ongoing symptoms, acute illness severity, and quality of life. Standardized telemedicine notes from acute illness were used for covariates (comorbidities and provider-assessed symptom severity). Bivariate and multivariable analyses were performed to assess predictors of persistent symptoms.Results Two hundred and ninety patients completed the survey, of whom 115 (39.7%) reported persistent symptoms including fatigue (n= 59, 20.3%), dyspnea on exertion (n=41, 14.1%), and mental fog (n=39, 13.5%) among others. Proportion of persistent symptoms did not differ based on duration since illness (<90 days: n=32, 37.2% versus >90 days: n=80, 40.4%, p = 0.61). Predictors of persistent symptoms included provider-assessed moderate-severe illness (aOR 3.24, 95% CI 1.75, 6.02), female sex (aOR 1.99 95% 0.98, 4.04; >90 days out: aOR 2.24 95% CI 1.01, 4.95), and middle age (aOR 2.08 95% CI 1.07, 4.03). Common symptoms associated with reports of worse physical health included weakness, fatigue, myalgias, and mental fog.Conclusions Symptoms following acute COVID-19 are common and may be predicted by factors during the acute phase of illness. Fatigue and neuropsychiatric symptoms figured prominently. Select symptoms seem to be particularly associated with perceptions of physical health following COVID-19 and warrant specific attention on future studies of PASC.Competing Interest StatementJO received grant funding from Regeneron Pharmaceuticals, Inc. for a study of Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts unrelated to this work. Funding StatementThis work was supported by the Georgia Geriatrics Workforce Enhancement Program COVID-19 Telehealth award, which is supported by the Health Resources and Services Administration (HRSA) of the US Department of Health and Human Services (HHS) as part of award number T1MHP39056 totaling US $90,625, with 0% financed with non-governmental sources. The contents of this paper are those of the authors and do not necessarily represent the official views of, nor an endorsement by, the HRSA, the HHS, or the US Government.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Emory IRB approval, STUDY00000920: Long-Term Health and Economic Impacts of COVID-19All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDeidentified data available upon reasonable request to the corresponding author. ER -